TRAIL-based therapy in pediatric bone tumors: how to overcome resistance

被引：18

作者：

Guiho, Romain ^{[1
,2
,3
]}

Biteau, Kevin ^{[1
,2
,3
]}

Heymann, Dominique ^{[1
,2
,3
]}

Redini, Francoise ^{[1
,2
,3
]}

机构：

[1] INSERM, Nantes, France

[2] Equipe Labellisee LIGUE CANC 2012, F-44035 Nantes, France

[3] Univ Nantes, Fac Med, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, F-44035 Nantes, France

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 03期

关键词：

Ewing's sarcoma; microenvironment; osteosarcoma; resistance; TRAIL; APOPTOSIS-INDUCING LIGAND; MESENCHYMAL STEM-CELLS; EWINGS-SARCOMA FAMILY; DEATH RECEPTOR 5; MONOCLONAL-ANTIBODY; AGONIST ANTIBODY; NECROSIS; OSTEOSARCOMA; HYPOXIA; CANCER;

D O I：

10.2217/fon.14.293

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Osteosarcoma and Ewing's sarcoma, the two most frequent malignant primary tumors preferentially arise in children and young adults, and have a poor prognosis. TRAIL represents a promising therapeutic approach for most cancers but in the case of primary bone tumors, osteosarcoma cell lines are highly resistant to this pro-apoptotic cytokine. In addition, another signaling pathway mediating cell proliferation and migration may be even activated in this subset of resistant cells leading to protumoral effect. Therapeutic perspectives are linked to possibility to overcome TRAIL resistance by combining other drugs with TRAIL or death receptors agonistic antibodies. We hypothesized that the bone microenvironment may provide a favorable niche for TRAIL resistance that might be targeted by new resensitizing agents.

引用

收藏

页码：535 / 542

页数：8

相关论文

共 64 条

[1]

Type I interferon and TNFα cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells [J].

Abadie, A ;

Besançon, F ;

Wietzerbin, J .

ONCOGENE, 2004, 23 (28) :4911-4920

[2]

TRAIL receptor signaling and therapeutics [J].

Abdulghani, Junaid ;

El-Deiry, Wafik S. .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (10) :1091-1108

[3]

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 [J].

Adams, C. ;

Totpal, K. ;

Lawrence, D. ;

Marsters, S. ;

Pitti, R. ;

Yee, S. ;

Ross, S. ;

Deforge, L. ;

Koeppen, H. ;

Sagolla, M. ;

Compaan, D. ;

Lowman, H. ;

Hymowitz, S. ;

Ashkenazi, A. .

CELL DEATH AND DIFFERENTIATION, 2008, 15 (04) :751-761

[4]

Hypoxia Modulates EWS-FLI1 Transcriptional Signature and Enhances the Malignant Properties of Ewing's Sarcoma Cells In vitro [J].

Aryee, Dave N. T. ;

Niedan, Stephan ;

Kauer, Maximilian ;

Schwentner, Raphaela ;

Bennani-Baiti, Idriss M. ;

Ban, Jozef ;

Muehlbacher, Karin ;

Kreppel, Michael ;

Walker, Robert L. ;

Meltzer, Paul ;

Poremba, Christopher ;

Kofler, Reinhard ;

Kovar, Heinrich .

CANCER RESEARCH, 2010, 70 (10) :4015-4023

[5]

Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL) [J].

Ashkenazi, Avi ;

Holland, Pamela ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3621-3630

[6]

Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family [J].

Azijli, K. ;

Weyhenmeyer, B. ;

Peters, G. J. ;

de Jong, S. ;

Kruyt, F. A. E. .

CELL DEATH AND DIFFERENTIATION, 2013, 20 (07) :858-868

[7]

Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro [J].

Barti-Juhasz, Helga ;

Mihalik, Rudolf ;

Nagy, Katalin ;

Grisendi, Giulia ;

Dominici, Massimo ;

Petak, Istvan .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03)

[8]

Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy [J].

Bouralexis, S ;

Findlay, DM ;

Atkins, GJ ;

Labrinidis, A ;

Hay, S ;

Evdokiou, A .

BRITISH JOURNAL OF CANCER, 2003, 89 (01) :206-214

[9]

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway [J].

Chaudhary, PM ;

Eby, M ;

Jasmin, A ;

Bookwalter, A ;

Murray, J ;

Hood, L .

IMMUNITY, 1997, 7 (06) :821-830

[10]

Hypoxia, HIF1 and glucose metabolism in the solid tumour [J].

Denko, Nicholas C. .

NATURE REVIEWS CANCER, 2008, 8 (09) :705-713

← 1 2 3 4 5 6 7 →